FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309683917> ?p ?o ?g. }

• W4309683917 endingPage "2534" @default.
• W4309683917 startingPage "2534" @default.
• W4309683917 abstract "Previously, we found that exogenous ganglioside GM3 had an antiatherosclerotic efficacy and that its antiatherosclerotic efficacy could be enhanced by reconstituted high-density lipoprotein (rHDL). In this study, we hypothesized that GM3-functionalized rHDL (i.e., GM3-rHDL) as a nanocarrier can promote the efficacy of traditional antiatherosclerotic drugs (e.g., statins). To test this hypothesis, lovastatin (LT) was used as a representative of statins, and LT-loaded GM3-rHDL nanoparticle (LT-GM3-rHDL or LT@GM3-rHDL; a mean size of ~142 nm) and multiple controls (e.g., GM3-rHDL without LT, LT-loaded rHDL or LT-rHDL, and other nanoparticles) were prepared. By using two different microsphere-based methods, the presences of apolipoprotein A-I (apoA-I) and/or GM3 in nanoparticles and the apoA-I-mediated macrophage-targeting ability of apoA-I/rHDL-containing nanoparticles were verified in vitro. Moreover, LT-GM3-rHDL nanoparticle had a slowly sustained LT release in vitro and the strongest inhibitory effect on the foam cell formation of macrophages (a key event of atherogenesis). After single administration of rHDL-based nanoparticles, a higher LT concentration was detected shortly in the atherosclerotic plaques of apoE-/- mice than non-rHDL-based nanoparticles, suggesting the in vivo plaque-targeting ability of apoA-I/rHDL-containing nanoparticles. Finally, among all nanoparticles LT-GM3-rHDL induced the largest decreases in the contents of blood lipids and in the areas of atherosclerotic plaques at various aortic locations in apoE-/- mice fed a high-fat diet for 12 weeks, supporting that LT-GM3-rHDL has the best in vivo antiatherosclerotic efficacy among the tested nanoparticles. Our data imply that GM3-functionalized rHDL (i.e., GM3-rHDL) can be utilized as a novel nanocarrier to enhance the efficacy of traditional antiatherosclerotic drugs (e.g., statins)." @default.
• W4309683917 created "2022-11-29" @default.
• W4309683917 creator A5009507517 @default.
• W4309683917 creator A5012748089 @default.
• W4309683917 creator A5017943466 @default.
• W4309683917 creator A5025967148 @default.
• W4309683917 creator A5030691366 @default.
• W4309683917 creator A5047323439 @default.
• W4309683917 creator A5066033995 @default.
• W4309683917 creator A5071000866 @default.
• W4309683917 date "2022-11-20" @default.
• W4309683917 modified "2023-09-26" @default.
• W4309683917 title "Ganglioside GM3-Functionalized Reconstituted High-Density Lipoprotein (GM3-rHDL) as a Novel Nanocarrier Enhances Antiatherosclerotic Efficacy of Statins in apoE−/− C57BL/6 Mice" @default.
• W4309683917 cites W1995812631 @default.
• W4309683917 cites W2002429753 @default.
• W4309683917 cites W2026525225 @default.
• W4309683917 cites W2070412958 @default.
• W4309683917 cites W2075521560 @default.
• W4309683917 cites W2075650741 @default.
• W4309683917 cites W2082101214 @default.
• W4309683917 cites W2110960044 @default.
• W4309683917 cites W2114991100 @default.
• W4309683917 cites W2132906575 @default.
• W4309683917 cites W2154023449 @default.
• W4309683917 cites W2164637490 @default.
• W4309683917 cites W2170695692 @default.
• W4309683917 cites W2219921058 @default.
• W4309683917 cites W2565687194 @default.
• W4309683917 cites W2590798727 @default.
• W4309683917 cites W2618238658 @default.
• W4309683917 cites W2786036329 @default.
• W4309683917 cites W2786120256 @default.
• W4309683917 cites W2790239792 @default.
• W4309683917 cites W2795058338 @default.
• W4309683917 cites W2800387553 @default.
• W4309683917 cites W2890194064 @default.
• W4309683917 cites W2948712759 @default.
• W4309683917 cites W2972487331 @default.
• W4309683917 cites W3000326550 @default.
• W4309683917 cites W3000797625 @default.
• W4309683917 cites W3045819362 @default.
• W4309683917 cites W3098500676 @default.
• W4309683917 cites W3103250047 @default.
• W4309683917 cites W3123567452 @default.
• W4309683917 cites W3198304777 @default.
• W4309683917 cites W4200509677 @default.
• W4309683917 cites W4207025723 @default.
• W4309683917 cites W4220966237 @default.
• W4309683917 cites W4281613713 @default.
• W4309683917 doi "https://doi.org/10.3390/pharmaceutics14112534" @default.
• W4309683917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36432725" @default.
• W4309683917 hasPublicationYear "2022" @default.
• W4309683917 type Work @default.
• W4309683917 citedByCount "3" @default.
• W4309683917 countsByYear W43096839172023 @default.
• W4309683917 crossrefType "journal-article" @default.
• W4309683917 hasAuthorship W4309683917A5009507517 @default.
• W4309683917 hasAuthorship W4309683917A5012748089 @default.
• W4309683917 hasAuthorship W4309683917A5017943466 @default.
• W4309683917 hasAuthorship W4309683917A5025967148 @default.
• W4309683917 hasAuthorship W4309683917A5030691366 @default.
• W4309683917 hasAuthorship W4309683917A5047323439 @default.
• W4309683917 hasAuthorship W4309683917A5066033995 @default.
• W4309683917 hasAuthorship W4309683917A5071000866 @default.
• W4309683917 hasBestOaLocation W43096839171 @default.
• W4309683917 hasConcept C12554922 @default.
• W4309683917 hasConcept C150903083 @default.
• W4309683917 hasConcept C155672457 @default.
• W4309683917 hasConcept C171250308 @default.
• W4309683917 hasConcept C18150654 @default.
• W4309683917 hasConcept C185592680 @default.
• W4309683917 hasConcept C192562407 @default.
• W4309683917 hasConcept C207001950 @default.
• W4309683917 hasConcept C2778163477 @default.
• W4309683917 hasConcept C2780072125 @default.
• W4309683917 hasConcept C55493867 @default.
• W4309683917 hasConcept C86803240 @default.
• W4309683917 hasConcept C98274493 @default.
• W4309683917 hasConceptScore W4309683917C12554922 @default.
• W4309683917 hasConceptScore W4309683917C150903083 @default.
• W4309683917 hasConceptScore W4309683917C155672457 @default.
• W4309683917 hasConceptScore W4309683917C171250308 @default.
• W4309683917 hasConceptScore W4309683917C18150654 @default.
• W4309683917 hasConceptScore W4309683917C185592680 @default.
• W4309683917 hasConceptScore W4309683917C192562407 @default.
• W4309683917 hasConceptScore W4309683917C207001950 @default.
• W4309683917 hasConceptScore W4309683917C2778163477 @default.
• W4309683917 hasConceptScore W4309683917C2780072125 @default.
• W4309683917 hasConceptScore W4309683917C55493867 @default.
• W4309683917 hasConceptScore W4309683917C86803240 @default.
• W4309683917 hasConceptScore W4309683917C98274493 @default.
• W4309683917 hasFunder F4320321001 @default.
• W4309683917 hasIssue "11" @default.
• W4309683917 hasLocation W43096839171 @default.
• W4309683917 hasLocation W43096839172 @default.
• W4309683917 hasLocation W43096839173 @default.
• W4309683917 hasLocation W43096839174 @default.
• W4309683917 hasOpenAccess W4309683917 @default.

• next